close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

2.230 -0.240 (-9.72%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
22 23 Next >
News headline image
Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Is It Too Late to Buy Iovance Biotherapeutics Stock? ↗
The stock is down more than 50% from its 52-week high. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
3 Top Penny Stocks to Skyrocket Your Wealth in 2024 ↗
Find out about the top penny stocks to buy this year for a chance to see incredible results down the road as they soar to new heights. 
Via InvestorPlace
News headline image
What's Going On With Iovance Biotherapeutics Today? ↗
On Thursday, Iovance revealed updated clinical findings for lifileucel in conjunction with pembrolizumab as a treatment for frontline advanced melanoma, as well as implementation data, to be presented... 
Via Benzinga
News headline image
Iovance Biotherapeutics's Options: A Look at What the Big Money is Thinking ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Iovance Biotherapeutics? ↗
 
Via Benzinga
News headline image
The Case for Buying Iovance Biotherapeutics Stock Just Got Even Better. Here's Why ↗
New data indicate that its cell therapy could soon find a larger market. 
Via The Motley Fool
News headline image
Oncotelic Therapeutics (OTC: OTLC) Inks Deal With Mosaic ImmunoEngineering To Sell Clinical-Stage Necroptosis Cancer Therapy Assets
Oncotelic Therapeutics (OTC: OTLC) Inks Deal With Mosaic ImmunoEngineering To Sell Clinical-Stage Necroptosis Cancer Therapy Assets 
Via News Direct
News headline image
Iovance Biotherapeutics to Present at Upcoming Conferences and Events
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Bull Market Buys: 2 Growth Stocks to Own for the Long Run ↗
These biotech stocks have just launched their first products. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
4 Small-Cap Value Stocks That Could Go Parabolic ↗
These four small-cap stocks scan as deeply undervalued right now. 
Via The Motley Fool
News headline image
The 3 Most Undervalued Biotech Stocks to Buy in May 2024 ↗
Three most undervalued biotech stocks to buy now will take off in the coming years and bring back continuous, hefty returns. 
Via InvestorPlace
News headline image
Why Iovance Stock Is Down 18% Today ↗
Investors are misunderstanding when the biopharma company's flagship drug will begin generating meaningful reportable revenue. 
Via The Motley Fool
News headline image
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
IOVA Stock Earnings: Iovance Biotherapeutics Meets EPS, Misses Revenue for Q1 2024 ↗
IOVA stock results show that Iovance Biotherapeutics met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Got $500? These Hot Growth Stocks Are Screaming Buys Right Now ↗
The time to jump into a red-hot growth prospect is usually right now...before any more investors identify the opportunity. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Where Will Iovance Biotherapeutics Stock Be in 5 Years? ↗
Is this rising healthcare stock a good buy right now? 
Via The Motley Fool
News headline image
The Top 3 Biotech Stocks to Buy in April 2024 ↗
Learn about the top three biotech stocks to take advantage of these companies' promising futures and pharmaceutical advances. 
Via InvestorPlace
News headline image
3 Millionaire-Maker Biotech Stocks ↗
The risk at these companies is above average, and they're sure to remain volatile. This volatility, however, includes explosively bullish potential. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
Oral Presentation of Updated Results of IOV-COM-202 Cohort 1A of Lifileucel plus Pembrolizumab in Advanced Frontline Melanoma 
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
These Biotech Stocks Could Soar 120% and 295%, According to Wall Street ↗
Catalysts lie ahead for both of these companies. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today